Breakthrough invasive fungal diseases in acute myeloid leukemia patients receiving mould active triazole primary prophylaxis after intensive chemotherapy: An Italian consensus agreement on definitions and management

Corrado Girmenia; Alessandro Busca; Anna Candoni; Simone Cesaro; Mario Luppi; Anna Maria Nosari; Livio Pagano; Giuseppe Rossi; Adriano Venditti; Franco Aversa

doi:10.1093/mmy/myy091

Breakthrough invasive fungal diseases in acute myeloid leukemia patients receiving mould active triazole primary prophylaxis after intensive chemotherapy: An Italian consensus agreement on definitions and management

Corrado Girmenia
, Alessandro Busca
, Anna Candoni
, Simone Cesaro
, Mario Luppi
, Anna Maria Nosari
, Livio Pagano
, Giuseppe Rossi
, Adriano Venditti
, Franco Aversa

University of Rome La Sapienza
Azienda Ospedaliera - Universitaria Città della Salute e della Scienza di Torino
University of Udine
Ospedale Policlinico
AOU Modena. UNIMORE
Asst Grande Ospedale Metropolitano Niguarda
Spedali Civili Di Brescia
University of Rome Tor Vergata
University of Parma

Research output: Contribution to journal › Article

6 Citations (Scopus)

Abstract

In the attempt to establish definitions and provide shared approaches to breakthrough invasive fungal diseases (br-IFD) in acute myeloid leukemia (AML) patients submitted to intensive chemotherapy and receiving triazoles as mould active primary antifungal prophylaxis (MA-PAP), literature on br-IFD in AML patients receiving triazoles MA-PAP was reviewed and a Consensus Development Conference Project was convened. The following four candidate key-questions were generated and formed the set of questions of the present document: "definition of br-IFD," "diagnostic strategy during MA-PAP to detect br-IFD," "possible causes of MA-PAP failure," "management of br-IFD."

Original language	English
Pages (from-to)	S127-S137-S137
Number of pages	11
Journal	Medical Mycology
Volume	57
DOIs	https://doi.org/10.1093/mmy/myy091
Publication status	Published - 2019

Keywords

acute myeloid leukemia
antifungal prophylaxis
breakthrough fungal infections
triazoles

Access to Document

10.1093/mmy/myy091

Fingerprint

Dive into the research topics of 'Breakthrough invasive fungal diseases in acute myeloid leukemia patients receiving mould active triazole primary prophylaxis after intensive chemotherapy: An Italian consensus agreement on definitions and management'. Together they form a unique fingerprint.

Cite this

Girmenia, C., Busca, A., Candoni, A., Cesaro, S., Luppi, M., Nosari, A. M., Pagano, L., Rossi, G., Venditti, A., & Aversa, F. (2019). Breakthrough invasive fungal diseases in acute myeloid leukemia patients receiving mould active triazole primary prophylaxis after intensive chemotherapy: An Italian consensus agreement on definitions and management. Medical Mycology, 57, S127-S137-S137. https://doi.org/10.1093/mmy/myy091

@article{5d39a371e8d3497fa1249f157c08c8ee,

title = "Breakthrough invasive fungal diseases in acute myeloid leukemia patients receiving mould active triazole primary prophylaxis after intensive chemotherapy: An Italian consensus agreement on definitions and management",

abstract = "In the attempt to establish definitions and provide shared approaches to breakthrough invasive fungal diseases (br-IFD) in acute myeloid leukemia (AML) patients submitted to intensive chemotherapy and receiving triazoles as mould active primary antifungal prophylaxis (MA-PAP), literature on br-IFD in AML patients receiving triazoles MA-PAP was reviewed and a Consensus Development Conference Project was convened. The following four candidate key-questions were generated and formed the set of questions of the present document: {"}definition of br-IFD,{"} {"}diagnostic strategy during MA-PAP to detect br-IFD,{"} {"}possible causes of MA-PAP failure,{"} {"}management of br-IFD.{"}",

keywords = "acute myeloid leukemia, antifungal prophylaxis, breakthrough fungal infections, triazoles, acute myeloid leukemia, antifungal prophylaxis, breakthrough fungal infections, triazoles",

author = "Corrado Girmenia and Alessandro Busca and Anna Candoni and Simone Cesaro and Mario Luppi and Nosari, \{Anna Maria\} and Livio Pagano and Giuseppe Rossi and Adriano Venditti and Franco Aversa",

year = "2019",

doi = "10.1093/mmy/myy091",

language = "English",

volume = "57",

pages = "S127--S137--S137",

journal = "Medical Mycology",

issn = "1369-3786",

publisher = "Oxford University Press",

}

Girmenia, C, Busca, A, Candoni, A, Cesaro, S, Luppi, M, Nosari, AM, Pagano, L, Rossi, G, Venditti, A & Aversa, F 2019, 'Breakthrough invasive fungal diseases in acute myeloid leukemia patients receiving mould active triazole primary prophylaxis after intensive chemotherapy: An Italian consensus agreement on definitions and management', Medical Mycology, vol. 57, pp. S127-S137-S137. https://doi.org/10.1093/mmy/myy091

Breakthrough invasive fungal diseases in acute myeloid leukemia patients receiving mould active triazole primary prophylaxis after intensive chemotherapy: An Italian consensus agreement on definitions and management. / Girmenia, Corrado; Busca, Alessandro; Candoni, Anna et al.
In: Medical Mycology, Vol. 57, 2019, p. S127-S137-S137.

Research output: Contribution to journal › Article

TY - JOUR

T1 - Breakthrough invasive fungal diseases in acute myeloid leukemia patients receiving mould active triazole primary prophylaxis after intensive chemotherapy: An Italian consensus agreement on definitions and management

AU - Girmenia, Corrado

AU - Busca, Alessandro

AU - Candoni, Anna

AU - Cesaro, Simone

AU - Luppi, Mario

AU - Nosari, Anna Maria

AU - Pagano, Livio

AU - Rossi, Giuseppe

AU - Venditti, Adriano

AU - Aversa, Franco

PY - 2019

Y1 - 2019

N2 - In the attempt to establish definitions and provide shared approaches to breakthrough invasive fungal diseases (br-IFD) in acute myeloid leukemia (AML) patients submitted to intensive chemotherapy and receiving triazoles as mould active primary antifungal prophylaxis (MA-PAP), literature on br-IFD in AML patients receiving triazoles MA-PAP was reviewed and a Consensus Development Conference Project was convened. The following four candidate key-questions were generated and formed the set of questions of the present document: "definition of br-IFD," "diagnostic strategy during MA-PAP to detect br-IFD," "possible causes of MA-PAP failure," "management of br-IFD."

AB - In the attempt to establish definitions and provide shared approaches to breakthrough invasive fungal diseases (br-IFD) in acute myeloid leukemia (AML) patients submitted to intensive chemotherapy and receiving triazoles as mould active primary antifungal prophylaxis (MA-PAP), literature on br-IFD in AML patients receiving triazoles MA-PAP was reviewed and a Consensus Development Conference Project was convened. The following four candidate key-questions were generated and formed the set of questions of the present document: "definition of br-IFD," "diagnostic strategy during MA-PAP to detect br-IFD," "possible causes of MA-PAP failure," "management of br-IFD."

KW - acute myeloid leukemia

KW - antifungal prophylaxis

KW - breakthrough fungal infections

KW - triazoles

KW - acute myeloid leukemia

KW - antifungal prophylaxis

KW - breakthrough fungal infections

KW - triazoles

UR - http://hdl.handle.net/10807/130347

U2 - 10.1093/mmy/myy091

DO - 10.1093/mmy/myy091

M3 - Article

SN - 1369-3786

VL - 57

SP - S127-S137-S137

JO - Medical Mycology

JF - Medical Mycology

ER -

Breakthrough invasive fungal diseases in acute myeloid leukemia patients receiving mould active triazole primary prophylaxis after intensive chemotherapy: An Italian consensus agreement on definitions and management

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this